Page last updated: 2024-11-05

n,n-diethylaniline

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

N,N-diethylaniline: a reagent and an intermediate in manufacturing of dyes [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID7061
CHEMBL ID252071
SCHEMBL ID17594
MeSH IDM0286921

Synonyms (84)

Synonym
BIDD:GT0823
nsc7205
n,n-diethylaminobenzene
diethylaniline
n,n-diethylaniline
phenyldiethylamine
nsc-7205
diaethylanilin
n,n-diethylanilin
diethylphenylamine
91-66-7
wln: 2n2&r
aniline, n,n-diethyl-
benzenamine, n,n-diethyl-
inchi=1/c10h15n/c1-3-11(4-2)10-8-6-5-7-9-10/h5-9h,3-4h2,1-2h
NCGC00091331-01
n,n-diethyl aniline
diaethylanilin [german]
hsdb 1639
un2432
ai3-52227
n,n-diethylbenzenamine
ccris 2847
einecs 202-088-8
n,n-diethylanilin [czech]
nsc 7205
n-phenyldiethylamine
benzamine, n,n-diethyl-
n,n-diethylaniline, >=99%
D0475
CHEMBL252071
smr001307329
MLS002303040
AKOS000119089
NCGC00091331-03
NCGC00091331-02
HMS3039C12
tox21_300569
NCGC00259047-01
NCGC00254308-01
dtxcid701800
cas-91-66-7
dtxsid8021800 ,
tox21_201496
diethyl-phenyl-amine
1wr1hj2pgw ,
unii-1wr1hj2pgw
n, n-diethylaniline [un2432] [poison]
ec 202-088-8
n, n-diethylaniline
FT-0629467
PS-6141
STL263867
SCHEMBL17594
diethylaniline [mi]
n,n-diethylaniline [hsdb]
diethyl aniline, n,n-
diethyl aniline
et2nph
diethylamino benzene
n,n-diethyl-aniline
n,n-diethyianiline
phnet2
n,n-diethyl-n-phenylamine #
un 2432
(diethylamino)benzene
358731-12-1
J-523236
n,n-dethylanlne
F0001-2220
Z57770738
mfcd00009042
n,n-diethylaniline, puriss. p.a., >=99.5%
n,n-diethylaniline, purum, >=98.0% (gc)
n,n-diethylaniline, 98%
mfcd31699978
n,n-diethylaniline-4-d
SY246295
2065185-74-0
Q1482984
n,n-di(ethyl-1,1-d2)aniline
n,n-di(ethyl-2,2,2-d3)aniline
n,n-diethylaniline 100 microg/ml in methanol
EN300-18282

Research Excerpts

Toxicity

ExcerptReferenceRelevance
"We previously found that N,N-diethylaniline increased the frequency of sister chromatid exchange (SCE) of human lymphocytes to about five times that of the control value, and was as toxic as cyclophosphamide used as a positive control for SCE."( Immunotoxicity of N,N-diethylaniline in mice: effect on natural killer activity, cytotoxic T lymphocyte activity, lymphocyte proliferation response and cellular components of the spleen.
Hirata, Y; Li, Q; Minami, M; Piao, S, 2000
)
0.94

Dosage Studied

ExcerptRelevanceReference
" ANOVA analyses indicated that there is a dose-response relationship between doses of N,N-diethylaniline and the frequency of SCEs, especially in the presence of S-9 mix."( Sister chromatid exchanges of human peripheral blood lymphocytes induced by N,N-diethylaniline in vitro.
Li, Q; Minami, M, 1997
)
0.75
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (7)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
retinoid X nuclear receptor alphaHomo sapiens (human)Potency24.54120.000817.505159.3239AID1159527; AID1159531
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency23.03530.001530.607315,848.9004AID1224841; AID1259401; AID1259403
estrogen nuclear receptor alphaHomo sapiens (human)Potency17.62710.000229.305416,493.5996AID743078
bromodomain adjacent to zinc finger domain 2BHomo sapiens (human)Potency0.70790.707936.904389.1251AID504333
aryl hydrocarbon receptorHomo sapiens (human)Potency69.56730.000723.06741,258.9301AID743085
chromobox protein homolog 1Homo sapiens (human)Potency89.12510.006026.168889.1251AID540317
gemininHomo sapiens (human)Potency14.66200.004611.374133.4983AID624296; AID624297
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (14)

Assay IDTitleYearJournalArticle
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID310931Partition coefficient, log P of the compound2007Journal of medicinal chemistry, Feb-22, Volume: 50, Issue:4
In silico and in vitro filters for the fast estimation of skin permeation and distribution of new chemical entities.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (14)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's1 (7.14)18.2507
2000's5 (35.71)29.6817
2010's7 (50.00)24.3611
2020's1 (7.14)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 38.84

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index38.84 (24.57)
Research Supply Index2.71 (2.92)
Research Growth Index4.81 (4.65)
Search Engine Demand Index53.49 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (38.84)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other14 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]